Shedding of clinical-grade lentiviral vectors is not detected in a gene therapy setting

Gene Therapy
M CesaniA Biffi

Abstract

Gene therapy using viral vectors that stably integrate into ex vivo cultured cells holds great promises for the treatment of monogenic diseases as well as cancer. However, carry-over of infectious vector particles has been described to occur upon ex vivo transduction of target cells. This, in turn, may lead to inadvertent spreading of viral particles to off-target cells in vivo, raising concerns for potential adverse effects, such as toxicity of ectopic transgene expression, immunogenicity from in vivo transduced antigen-presenting cells and, possibly, gene transfer to germline cells. Here, we have investigated factors influencing the extent of lentiviral vector (LV) shedding upon ex vivo transduction of human hematopoietic stem and progenitor cells. Our results indicate that, although vector carry-over is detectable when using laboratory-grade vector stocks, the use of clinical-grade vector stocks strongly decreases the extent of inadvertent transduction of secondary targets, likely because of the higher degree of purification. These data provide supportive evidence for the safe use of the LV platform in clinical settings.

References

Oct 10, 1998·Journal of Virology·T DullL Naldini
Sep 14, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·N J DePoloT W Dubensky
May 23, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Giampaolo GrecoLynn M Schnapp
Jun 20, 2002·Journal of Virology·Simon J WalkerStephen Devereux
Sep 2, 2006·Science·Richard A MorganSteven A Rosenberg
Nov 3, 2006·The Journal of Clinical Investigation·Alessandra BiffiLuigi Naldini
Nov 9, 2006·Proceedings of the National Academy of Sciences of the United States of America·Bruce L LevineCarl H June
Dec 1, 2007·Nature Methods·Manfred SchmidtChristof von Kalle
May 5, 2010·The Journal of Gene Medicine·Lee S O'NeillPeter Kurre
Sep 17, 2010·Nature·Marina Cavazzana-CalvoPhilippe Leboulch
Aug 13, 2011·The New England Journal of Medicine·David L PorterCarl H June
Mar 1, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Samantha ScaramuzzaAlessandro Aiuti

❮ Previous
Next ❯

Citations

Jul 7, 2017·Gene Therapy·D A Monfort, P Koria
Aug 31, 2018·Journal of Cellular Biochemistry·Zahra PayandehSiavoush Dastmalchi
Sep 26, 2020·Gene Therapy·Iris J C DautzenbergRob C Hoeben
May 14, 2021·Molecular Therapy. Methods & Clinical Development·Nathan M JohnsonStephen E Braun
Jan 1, 2020·Molecular Therapy. Methods & Clinical Development·Matthew BaulerRobert E Throm

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.